To hear about similar clinical trials, please enter your email below
Trial Title:
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
NCT ID:
NCT05761366
Condition:
Malignancy
Conditions: Official terms:
Neoplasms
PSMA-BCH
Conditions: Keywords:
Malignancy
Prostate Specific Membrane Antigen Positive Tumor
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Al18F-PSMA-BCH PET/CT
Description:
Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Arm group label:
Al18F-PSMA-BCH PET/CT
Other name:
18F-Thretide PET/CT
Summary:
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific
membrane antigen positive tumor, to evaluate the tumour detection efficacy of
Al18F-PSMA-BCH PET/CT.
Detailed description:
Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed
PSMA positive-expressing tumors (including prostate cancer, transitional epithelial
carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular
carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour
detection efficacy of Al18F-PSMA-BCH PET/CT.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Patients with suspected or clearly diagnosed PSMA positive-expressing tumors,
including prostate cancer, transitional epithelial carcinoma, colon carcinoma,
adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma,
cholangiocellular carcinoma, multiple myeloma, etc.
2. Age is 18 or older; No gender limitation.
3. Signed the informed consent.
4. Willing and able to cooperate with all projects in this study.
Exclusion Criteria:
1. Patients with serious neurological diseases,or gastrointestinal tract disease,
cardiovascular disease, liver disease, kidney disease, blood system disease,
endocrine system disease, respiratory system disease, immune deficiency disease, etc
2. Claustrophobia.
3. Pregnant or lactation women.
4. Received experimental drug or device within 1 month.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Address:
City:
Beijing
Zip:
100029
Country:
China
Status:
Recruiting
Contact:
Last name:
Xin Cheng, MD
Phone:
15120002998
Email:
cxpumc@foxmail.com
Start date:
October 13, 2022
Completion date:
October 13, 2025
Lead sponsor:
Agency:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Agency class:
Other
Source:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05761366
